JP2013545087A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545087A5
JP2013545087A5 JP2013534031A JP2013534031A JP2013545087A5 JP 2013545087 A5 JP2013545087 A5 JP 2013545087A5 JP 2013534031 A JP2013534031 A JP 2013534031A JP 2013534031 A JP2013534031 A JP 2013534031A JP 2013545087 A5 JP2013545087 A5 JP 2013545087A5
Authority
JP
Japan
Prior art keywords
patient
level
sci
predefined
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013534031A
Other languages
English (en)
Japanese (ja)
Other versions
JP6071886B2 (ja
JP2013545087A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/056338 external-priority patent/WO2012051519A2/en
Publication of JP2013545087A publication Critical patent/JP2013545087A/ja
Publication of JP2013545087A5 publication Critical patent/JP2013545087A5/ja
Application granted granted Critical
Publication of JP6071886B2 publication Critical patent/JP6071886B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013534031A 2010-10-14 2011-10-14 脳損傷のバイオマーカー Active JP6071886B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US39300910P 2010-10-14 2010-10-14
US61/393,009 2010-10-14
US201161436956P 2011-01-27 2011-01-27
US201161436955P 2011-01-27 2011-01-27
US61/436,955 2011-01-27
US61/436,956 2011-01-27
PCT/US2011/056338 WO2012051519A2 (en) 2010-10-14 2011-10-14 Biomarkers of brain injury

Publications (3)

Publication Number Publication Date
JP2013545087A JP2013545087A (ja) 2013-12-19
JP2013545087A5 true JP2013545087A5 (enExample) 2014-12-04
JP6071886B2 JP6071886B2 (ja) 2017-02-01

Family

ID=45938999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013534031A Active JP6071886B2 (ja) 2010-10-14 2011-10-14 脳損傷のバイオマーカー

Country Status (5)

Country Link
US (2) US9746481B2 (enExample)
EP (1) EP2628013B1 (enExample)
JP (1) JP6071886B2 (enExample)
IL (1) IL225731B (enExample)
WO (1) WO2012051519A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019553A2 (en) 2008-08-11 2010-02-18 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US9709573B2 (en) 2012-03-13 2017-07-18 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
US9378551B2 (en) * 2013-01-03 2016-06-28 Siemens Aktiengesellschaft Method and system for lesion candidate detection
EP3022322A4 (en) * 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
JP6312302B2 (ja) * 2014-01-06 2018-04-18 公益財団法人ヒューマンサイエンス振興財団 脳梗塞の診断マーカー
EP2896702A1 (en) * 2014-01-16 2015-07-22 University College Cork, National University Of Irland Cork A method of identifying a neonate at risk of having or developing hypoxic-ischaemic encephalopathy (HIE)
US10238664B2 (en) * 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
US20180238907A1 (en) * 2014-10-06 2018-08-23 Université de Genéve Markers and their use in brain injury
US12422442B2 (en) 2014-10-06 2025-09-23 Universite De Geneve Markers and their use in brain injury
EP3254106A4 (en) 2015-02-05 2018-10-03 Immunarray USA, Inc. Methods and compositions for diagnosing brain injury or neurodegeneration
EP3292414B1 (en) 2015-05-05 2021-04-07 The Regents of the University of California Astrocyte traumatome and neurotrauma biomarkers
US20180106818A1 (en) * 2016-10-03 2018-04-19 Abbott Laboratories Methods of assessing gfap status in patient samples
US11078298B2 (en) 2016-10-28 2021-08-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
US20200191801A1 (en) * 2016-12-23 2020-06-18 Susanne PANGRATZ-FÜHRER Alpha-b crystallin in the diagnosis of neonatal brain damage
CN106645755B (zh) * 2016-12-30 2018-09-25 深圳大学 一种ad生物标记物及其检测方法
CA3050001A1 (en) 2017-01-13 2018-07-19 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
WO2018175942A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
EP3610268B1 (en) 2017-04-15 2025-09-24 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
BR112019022476A2 (pt) 2017-04-28 2020-05-12 Abbott Laboratories Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano
US11709168B2 (en) 2017-05-23 2023-07-25 Brainbox Solutions, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
WO2018218169A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
CA3059607A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i
JP7454945B2 (ja) 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
WO2019112863A1 (en) * 2017-12-06 2019-06-13 FloTBI Inc. Assay and point of care device utilizing saliva for diagnosis and treatment of neurological conditions affected brain health
BR112019028254A2 (pt) 2017-12-09 2020-07-14 Abbott Laboratories métodos para ajudar no diagnóstico e avaliação de um paciente que sofreu uma lesão ortopédica e que sofreu ou pode ter sofrido uma lesão na cabeça, tal como uma lesão cerebral traumática (lct) leve, usando a proteína ácida fibrilar glial (gfap) e/ou a hidrolase carbóxi-terminal da ubiquitina l1 (uch-l1)
CA3067055A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
EP3732489B1 (en) 2017-12-29 2025-10-22 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
CN108872589B (zh) * 2018-01-03 2021-09-03 深圳市人民医院 脑梗死外周血标志物及其应用
WO2019189725A1 (ja) * 2018-03-30 2019-10-03 国立研究開発法人国立精神・神経医療研究センター 新生児低酸素性虚血性脳症の重症度判定方法と予後予測方法
BR112021009203A2 (pt) * 2018-11-14 2021-08-03 Mark Evans método e aparelho para reduzir o risco de lesão neurológica a uma criança humana no período neonatal
US20220016221A1 (en) * 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
CN110261617B (zh) * 2019-05-14 2022-07-01 深圳市人民医院 脑出血外周血标志物及其应用
CN110907422B (zh) * 2019-12-16 2021-07-06 吉林大学 基于Ti3C2的凝血酶适体传感器及其制备方法
US20230088509A1 (en) * 2020-05-20 2023-03-23 St. Jude Children's Research Hospital Detection of alzheimer's disease using specific biomarkers
EP3982123A1 (en) * 2020-10-08 2022-04-13 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Markers and their use in brain injury
WO2022165431A1 (en) * 2021-02-01 2022-08-04 The University Of Chicago Systems and methods for identifying progression of hypoxic-ischemic brain injury

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3234412A (en) * 1961-07-21 1966-02-08 Babcock & Wilcox Co Thermionic conversion nuclear reactor
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
ATE160821T1 (de) 1990-06-11 1997-12-15 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
NZ267842A (en) 1993-05-28 1997-09-22 Baylor College Medicine Apparatus for measuring molecular mass (by mass spectrometry) in which the sample is ionised on the sample holder and desorbed therefrom by laser pulses
US5866434A (en) 1994-12-08 1999-02-02 Meso Scale Technology Graphitic nanotubes in luminescence assays
US6673533B1 (en) 1995-03-10 2004-01-06 Meso Scale Technologies, Llc. Multi-array multi-specific electrochemiluminescence testing
BR9607193B1 (pt) 1995-03-10 2009-01-13 teste de eletroquimioluscÊncia multi-especÍfico de méltiplos conjuntos.
US6207369B1 (en) 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
US6319670B1 (en) 1995-05-09 2001-11-20 Meso Scale Technology Llp Methods and apparatus for improved luminescence assays using microparticles
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6413783B1 (en) 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6780606B1 (en) 1999-02-26 2004-08-24 Synx Pharma, Inc. Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
EP1236173A2 (en) 1999-10-27 2002-09-04 Biowulf Technologies, LLC Methods and devices for identifying patterns in biological systems
SG144731A1 (en) 2000-07-18 2008-08-28 Correlogic Systems Inc A process for discriminating between biological states based on hidden patterns from biological data
AU2001291217A1 (en) 2000-09-22 2002-04-02 University Of Aarhus Novel compositions and methods for lymphoma and leukemia
US20020164576A1 (en) 2000-09-22 2002-11-07 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
AU2002241535B2 (en) 2000-11-16 2006-05-18 Ciphergen Biosystems, Inc. Method for analyzing mass spectra
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US7144708B2 (en) 2001-06-25 2006-12-05 The Cleveland Clinic Foundation Markers of blood barrier disruption and methods of using same
US6884591B2 (en) 2001-06-25 2005-04-26 The Cleveland Clinic Foundation Peripheral marker of blood brain barrier permeability
CA2451789C (en) 2001-06-29 2012-03-27 Meso Scale Technologies, Llc. Assay plates, reader systems and methods for luminescence test measurements
WO2003068947A1 (en) 2001-07-30 2003-08-21 Meso Scale Technologies, Llc. Assay electrodes having immobilized lipid/protein layers and methods of making and using the same
CA2457775A1 (en) 2001-08-20 2003-02-27 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
CA3081228C (en) 2001-09-10 2022-02-15 Meso Scale Technologies, Llc Assay buffer, compositions containing the same, and methods of using the same
WO2003022028A2 (en) 2001-09-10 2003-03-20 Meso Scale Technologies, Llc Methods, reagents, kits and apparatus for protein function analysis
US20070098728A1 (en) 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
WO2003048768A2 (en) 2001-12-05 2003-06-12 Sense Proteomic Limited Protein arrays for allelic variants and uses thereof
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
US7036946B1 (en) 2002-09-13 2006-05-02 Rockwell Collins, Inc. LCD backlight with UV light-emitting diodes and planar reactive element
AU2003302263A1 (en) 2002-12-26 2004-07-29 Meso Scale Technologies, Llc. Assay cartridges and methods of using the same
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US7981362B2 (en) 2003-11-04 2011-07-19 Meso Scale Technologies, Llc Modular assay plates, reader systems and methods for test measurements
US20140303041A1 (en) 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
EP1745149A4 (en) * 2004-04-15 2008-08-06 Univ Florida NEURALE PROTEINS AS BIOMARKERS FOR INJURY TO THE NERVOUS SYSTEM AND OTHER NEURAL DISORDERS
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
ES2367311T3 (es) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
WO2005121798A1 (en) 2004-06-03 2005-12-22 Meso Scale Technologies, Llc Methods and apparatuses for conducting assays
WO2006012351A2 (en) 2004-06-25 2006-02-02 Washington University Markers for brain damage
US20060257943A1 (en) 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
US7884260B2 (en) 2005-06-14 2011-02-08 University Of Chicago Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
WO2007123976A2 (en) 2006-04-18 2007-11-01 The Board Of Trustees Of The Leland Stanford Junior University Antibody profiling for determination of patient responsiveness
WO2007136617A2 (en) * 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
US8088584B2 (en) 2006-10-16 2012-01-03 Bayer Schering Pharma Aktiengesellschaft LTBP2 as a biomarker and diagnostic target
WO2008097618A1 (en) 2007-02-06 2008-08-14 University Of Florida Research Foundation, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
EP2015196A1 (en) 2007-06-28 2009-01-14 Siemens Aktiengesellschaft Programmer interface for manufacturing execution system
US8497078B2 (en) 2008-05-23 2013-07-30 The Johns Hopkins University Biomarkers for myocardial ischemia
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
WO2010019553A2 (en) 2008-08-11 2010-02-18 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20140342381A1 (en) 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
GB201008541D0 (en) * 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
MX2013008746A (es) 2011-01-28 2014-06-23 Immunosciences Lab Inc Metodo para la deteccion de permeabilidad intestinal y de la barrera hemato-encefalica y materiales de prueba para este.
WO2012155134A2 (en) * 2011-05-12 2012-11-15 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit
WO2012170998A1 (en) 2011-06-10 2012-12-13 Cornell University Immobilized protein system for rapid and enhanced multiplexed diagnostics
WO2013173596A1 (en) 2012-05-16 2013-11-21 Trustees Of Boston University Chronic traumatic encephalopathy in blast-exposed individuals
WO2014194329A1 (en) 2013-05-31 2014-12-04 Banyan Biomarkers, Inc. NEURAL SPECIFIC S100β FOR BIOMARKER ASSAYS AND DEVICES FOR DETECTION OF A NEUROLOGICAL CONDITION
WO2015066211A1 (en) 2013-10-29 2015-05-07 Banyan Biomarkers, Inc. Uch-l1 isoforms, assays and devices for detection of a neurological condition

Similar Documents

Publication Publication Date Title
JP2013545087A5 (enExample)
JP2015513370A5 (enExample)
Lee et al. CSF and brain indices of insulin resistance, oxidative stress and neuro-inflammation in early versus late Alzheimer’s disease
JP2016533499A5 (enExample)
Serrano-Pozo et al. A phenotypic change but not proliferation underlies glial responses in Alzheimer disease
Rota et al. Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients
Lista et al. Tracking neuroinflammatory biomarkers in Alzheimer’s disease: a strategy for individualized therapeutic approaches?
JP6061935B2 (ja) 心的外傷後ストレス障害（ｐｔｓｄ）のための診断用バイオマーカーを検出及び監視するため、並びに同障害の自殺型と非自殺型とを識別するためのプロセス及びキット
JP2014506244A5 (enExample)
JP2010524432A5 (enExample)
JP2009540309A (ja) 神経変性障害の診断および早期診断のためのｉｎｖｉｔｒｏマルチパラメータ測定法
WO2007136617A3 (en) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
RU2014117671A (ru) Способ диагностики болезни альцгеймера (ad)
Yu et al. Diagnostic utility of VEGF and soluble CD40L levels in serum of Alzheimer's patients
RU2015116674A (ru) Способ диагностики или мониторинга почечной функции или диагностики почечной дисфункции
JP2024096748A (ja) アルファ－シヌクレイン病のアッセイ、方法、及び治療
NL2007112C2 (en) Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
HRP20191862T1 (hr) Procjena rizika u liječenju antibioticima kod pacijenata koji boluju od primarne nezarazne bolesti određivanjem razine prokalcitonina
RU2009146803A (ru) Способ диагностики деструктивного панкреатита
BR112014007947A2 (pt) método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5
Ventura et al. Pancreatic Stone Protein Measurement to Screen and Diagnose Sepsis in the Context of the Surviving Sepsis Campaign Recommendations.
US20110129857A1 (en) Methods Of Detecting Or Monitoring Activity Of An Inflammatory Condition Or Neurodegenerative Condition
JP2015503106A5 (enExample)
US20140273032A1 (en) Compositions and methods for diagnosis of schizophrenia
Horie et al. Mass Spectrometry-Based Quantification of Orexin Species in Human Cerebrospinal Fluid Reveals Differential Dynamics Associated with Sleep